Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6003 in Healthy Adult Volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVI 6003 (Primary)
Indications Marburg virus disease
Focus Adverse reactions

Most Recent Events

16 Oct 2014 Results published in the November 2014 issue of the journal Antimicrobial Agents and Chemotherapy, according to a Sarepta Therapeutics media release.
16 Oct 2014 Results published in a Sarepta Therapeutics media release.
03 Apr 2012 Results were presented at the 22nd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com